Ascendis to investigate new indications following EU approval
Ascendis Pharma is ready to sell its growth hormone for children in the EU after Thursday's approval from the European Commission, but more indications are on the drawing board.
by ANDREAS LØNSTRUP, translated by daniel pedersen
On Thursday, Danish biotech firm Ascendis Pharma could celebrate the EU Commission's formal approval of Lonapegsomatropin, previously dubbed Transcon hGH, which is a once-weekly injection for pediatric patients with growth hormone deficiency (GHD).
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Biomarin's dwarfism drug receives FDA approval
For subscribers
Ascendis Pharma's growth hormone formally approved in the EU
For subscribers
